Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Diabetology International
Published in: Diabetology International 1/2010

01-11-2010 | Review article

Insulin autoimmune syndrome (Hirata disease): epidemiology in Asia, including Japan

Authors: Yasuko Uchigata, Yukimasa Hirata, Yasuhiko Iwamoto

Published in: Diabetology International | Issue 1/2010

Login to get access

Abstract

As populations with a higher prevalence of HLADRB1*0406 have been found to have a higher risk of developing insulin autoimmune syndrome (IAS), we report here the clinical features of Asian and Japanese IAS. There was female dominance in the 20- to 49-year-old age group at the onset of IAS development. Forty-two percent of Japanese IAS patients had received drugs or α-lipoic acid containing the sulfhydryl group, while 81% of Asian IAS patients outside Japan had received methimazole or carbimazole before the development of IAS.
Literature
1.
Hirata Y, Ishizu H, Ouchi N, et al. Insulin autoimmunity in a case of spontaneous hypoglycemia. J Jpn Diabetes Soc. 1970;13:312–20.
2.
Uchigata Y, Eguchi Y, Takayama-Hasumi S, et al. Insulin autoimmune syndrome (Hirata disease): clinical features and epidemiology in Japan. Diabetes Res Clin Pract. 1994;22:89–94.CrossRefPubMed
3.
Uchigata Y, Hirata Y, Omori Y, Iwamoto Y, Tokunaga K. Worldwide differences in incidence of insulin autoimmune syndrome (IAS, Hirata’s Disease) with respect to the evolution of HLA-DR4. Hum Genet. 2000;61:154–7.
4.
Lupsa BC, Chong AY, Cochran EK, Soos MA, Semple RK, Gorden P. Autoimmune forms of hypoglycemia. Medicine. 2009;88:141–53.CrossRefPubMed
5.
Uchigata Y, Omori Y. Clinical characteristics of 212 patients with insulin autoimmune syndrome (Hirata Disease) (in Japanese). Hormone Pract. 1994;42(Suppl):229–32.
6.
Hirata Y. Methimazole and insulin autoimmune syndrome with hypoglycemia. Lancet. 1983; ii:1037–1038.
7.
Uchigata Y, Kuwata S, Tsushima T, et al. Patients with Graves’ disease who developed insulin autoimmune syndrome (Hirata disease) possess HLA-Bw62/Cw4/DR4 carrying DRB1*0406. J Clin Endocrinol Metab. 1993;77:249–54.CrossRefPubMed
8.
Uchigata Y, Hirata Y, Iwamoto Y. Drug-induced insulin autoimmune syndrome. Diabetes Res Clin Pract. 2009;83:e19–20.CrossRefPubMed
9.
Wasada T, Eguchi Y, Takayama S, Hirata Y, Ishii S. Insulin autoimmune syndrome associated with benign monoclonal gammopathy. Diabetes Care. 1989;12:147–50.CrossRefPubMed
10.
Murakami M, Mizuida M, Kashima K, Kojima A, Tomioka SI, Kohama T, Araki O, Ogiwara T, Mizuma H, Mori M. Identification of monoclonal insulin autoantibodies in insulin autoimmune syndrome associated with HLA-DRB1*0404. Hormone Res. 2000;54:49–52.PubMed
11.
Miyake T, Tsujimura F, Ito Y. A case of monoclonal insulin autoimmune syndrome with a suspected 20-year history: effect of one-year administration of prednisolone on insulin autoantibodies. J Jpn Diab Soc. 2009;52:45–9.
12.
Uchigata Y, Tokunaga K, Nepom G, et al. Differential immunogenetic determinants of polyclonal insulin autoimmune syndrome (Hirata’s disease) and monoclonal insulin autoimmune syndrome. Diabetes. 1995;44:1227–32.CrossRefPubMed
13.
Masjhur JS. Insulin autoimmune syndrome (Hirata’s Disease): severe hypoglycemic episodes in Graves’s hyperthyroidism patient treated with methimazole. Acta Media Indonesiana. 2005;37:214–6.
14.
Uchigata Y, Omori Y, Nieda M, et al. HLA-DR4 genotype and insulin-processing in insulin autoimmune syndrome. Lancet. 1992;340:1467.CrossRefPubMed
15.
Ito Y, Nieda M, Uchigata Y, et al. Recognition of human insulin in the context of HLA-DRB1*0406 products by T cells of insulin autoimmune syndrome patients and healthy donors. J Immunol. 1993;15:5770–6.
16.
Miyamura N, Murata Y, Takeda K, Ichihara T, Matsumura H, Tokunaga K, Matsumoto M, Sakakida M, Araki E. A case of insulin autoimmune syndrome with HLADRB1*0404: impact on the hypothesis for the molecular pathogenesis involving DRB1 molecules. Diabet Med. 2006;23:103–6.CrossRef
17.
Kishikawa H, Okada Y, Hirose A, Kawahara T, Misawa H, Tanikawa T, Kanda K, Morita E, Tanaka Y. A case of insulin autoimmune syndrome whom the development of IAS was probably induced by Loxoprofen sodium. J Jpn Diab Soc. 2004;47:851–4.
18.
Benson EB, Ho P, Wang C, et al. Insulin autoimmunity as a cause of hypoglycemia. Arch Intern Med. 1984;144:2351–4.CrossRefPubMed
19.
Cho BY, Lee HK, Koh CS, et al. Spontaneous hypoglycemia and insulin autoantibodies in patients with Graves’ disease. Diabetes Res Clin Pract. 1987;3:119–24.CrossRefPubMed
20.
Lee Y-J, Shin S-J, Torng J-K, et al. Insulin autoimmune syndrome in a methimazole-treated Graves’ disease with polyclonal anti-insulin autoantibodies. J Formosa Med Assoc. 1987;867:164–70.
21.
Lin H-D, Chen H-D, Chang R-Y, Lin C-Y, Ching K-N. Insulin autoimmune syndrome in methimazole or carbimazole treated Chinese patients of Graves’ disease. Chin Med J. 1988;42:163–8.
22.
Wong ST, Ng WY, Thai AC. Case report: autoimmune insulin syndrome in a Chinese female with Graves’ disease. Ann Acad Med Singap. 1996;25:882–5.PubMed
23.
Chen C-H, Huang M-J, Huang B-Y, et al. Insulin autoimmune syndrome as a cause of hypoglycemia––report of four cases. Changgeng Yi Xue Za Zhi. 1990;13:134–42.PubMed
24.
Lu CC, Lee JK, Yang CY, Han TM. Insulin autoimmune syndrome in a patient with methimazole and carbimazole-treated Graves’ disease: a case report. Chin Med J. 1994;54(5):353–8.
25.
Ma WY, Won JG, Tang KT, Lin HD. Severe hypoglycemic coma due to insulin autoimmune syndrome. J Chin Med Assoc. 2005;68:82–6.CrossRefPubMed
Metadata
Title
Insulin autoimmune syndrome (Hirata disease): epidemiology in Asia, including Japan
Authors
Yasuko Uchigata
Yukimasa Hirata
Yasuhiko Iwamoto
Publication date
01-11-2010
Publisher
Springer Japan
Published in
Diabetology International / Issue 1/2010
Print ISSN: 2190-1678
Electronic ISSN: 2190-1686
DOI
https://doi.org/10.1007/s13340-010-0001-z

Other articles of this Issue 1/2010

Diabetology International 1/2010 Go to the issue

Report of the committee

Report of the Committee on the classification and diagnostic criteria of diabetes mellitus

Original article

Leptin mediates the relationship between abdominal obesity and microalbuminuria in type 2 diabetic patients

Editorial

Diabetology International: our new official journal in English

Original article

Efficacy and adverse effects of low-dose nateglinide in early type 2 diabetes: comparison with acarbose in a crossover study

Original article

Different effects of islet transplantation and Detemir treatment on the reversal of streptozotocin-induced diabetes associated with β-cell regeneration

Review article

Macrophage infiltration and cytokine release in adipose tissue: angiogenesis or inflammation?
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits